Compounds / BPC-157 and TB-500: studied together?

BPC-157 and TB-500

Also sold as the "Wolverine stack". Both are sold for healing injuries, and they are marketed together on the theory that they work through different mechanisms — one on blood-vessel growth, the other on cell migration. The combination is probably the most widely discussed peptide pairing there is.

This page answers one question: has anyone registered a trial of this combination? It is a different question from whether the ingredients have been studied separately, and the two answers are usually different. We do not publish doses, ratios or timing for any combination.

0On record
No trial on ClinicalTrials.gov lists this combination
We found no registered interventional trial on ClinicalTrials.gov that administers BPC-157 and TB-500 together. The individual compounds may have trials of their own — those are listed below — but a trial of one ingredient does not tell you what the mixture does. That is not a claim the combination is harmful or useless. It means the specific question has not been asked on the record.

The ingredients, separately

BPC-157
Body Protection Compound 157 · Pentadecapeptide
Marketed for four uses. The two registered human trials both study muscle injury, and one is still recruiting.
Studied on its own
2
Registered trials
TB-500
Thymosin Beta-4 fragment
The one human trial under this name is a heart study. Not a single registered trial tests it for the injury recovery it's sold for.
Studied on its own
1
Registered trials
Read this
Why combinations are studied separately
Two compounds given together can interact — in how they are absorbed, how long they last, or what they do at the same receptor. That is why regulators treat a fixed combination as its own product requiring its own trials. CagriSema is the example on this site of a combination developed and tested as one thing.

See all 42 compounds →